Cytokine modulation

Patent metadata

Field	Value
Publication number	US-2025127851-A1
Application number	US-202418820108-A
Country	US
Kind code	A1
Filing date	Aug 29, 2024
Priority date	Jul 19, 2017
Publication date	Apr 24, 2025
Grant date	—

Abstract

The inventions relate to the use of hemichannel blockers to modulate cytokine levels in a subject, including the angiogenic cytokine, VEGF, and their production, secretion and/or release, and to the use of hemichannel blockers to reduce or level cytokine activity, including in conditions characterized in whole or in part by angiogenesis and/or vessel leak.

First claim

We claim:

1 - 26 . (canceled)

27 . A method for modulating cytokine activity in a human subject, comprising administering to said human subject an amount of a benzoylamino benzopyran connexin 43 hemichannel blocker effective to reduce cytokine levels and/or activities in said subject, wherein the benzoylamino benzopyran connexin 43 hemichannel blocker is a compound according to Formula II and the cytokine is selected from the group consisting of interleukin-6 (IL-6), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), soluble intracellular adhesion molecule-1 (sICAM-1) and vascular endothelial growth factor (VEGF);

wherein
Q is O or an oxime,
R 2 is H,
A is a direct bond, —C(O)O*-, —C(R 3 )(R 4 )O *-, —C(O)O—C(R 3 )(R 4 )O*-, or —C(R 3 )(R 4 )OC(O)O*- wherein the atom marked * is directly connected to R 1 ,
R 3 and R 4 are selected independently from H, fluoro, C 1-4 alkyl, and C 1-4 fluoroalkyl, or R 3 and R 4 together with the atom to which they are attached form a cyclopropyl group,
R 1 is selected from groups [1], [2], [2A], [3], [4], [5] and [6] wherein the atom marked ** is directly connected to A:

wherein R 5 and R 6 are each independently selected from H, C 1-4 alkyl, C 1-4 fluoroalkyl, and benzyl;
R 7 is independently selected from H, C 1-4 alkyl, and C 1-4 fluoroalkyl;
R 8 is selected from:
(i) H, C 1-4 alkyl, or C 1-4 fluoroalkyl,
(ii) the side chain of a natural alpha-amino acid, and
(iii) biotin or chemically linked to biotin;

R 9 is selected from H, —N(R 11 )(R 12 ), —N + (R 11 )(R 12 ) (R 13 )X − , and —N(R 11 )C(O)R 14 ;
wherein R 11 , R 12 , and R 13 are independently selected from H, C 1-4 alkyl, and C 1-4 fluoroalkyl,
R 14 is H, C 1-4 alkyl, or C 1-4 fluoroalkyl,
R 15 is selected from C 1-4 alkyl and C 1-4 fluoroalkyl, and
X − is a pharmaceutically acceptable anion.

28 . The method of claim 27 , wherein the presence or amount of said cytokine is decreased.

29 . The method of claim 27 wherein an increase in the presence or amount of said cytokine is inhibited.

30 . The method of claim 27 , wherein the cytokine is selected from the group consisting of interleukin-6 (IL-6) and interleukin-8 (IL-8).

31 . The method of claim 27 , wherein the cytokine is selected from the group consisting of monocyte chemoattractant protein-1 (MCP-1) and soluble intracellular adhesion molecule-1 (sICAM-1).

32 . The method of claim 27 , wherein the vascular endothelial growth factor is vascular endothelial growth factor-A.

33 . The method of claim 27 , wherein the connexin 43 hemichannel blocker is less than about 600 Daltons.

34 . The method of claim 27 , wherein said human subject has a disease, disorder or condition characterized at least in part by pathologic or unwanted angiogenesis and the method optionally further comprises administering a VEGF antagonist or a VEGF receptor antagonist.

35 . The method of claim 34 , wherein the VEGF is VEGF-A.

36 . The method of claim 27 , wherein the method further comprises administering an IL-6 antagonist or an IL-6 receptor antagonist.

37 . The method of claim 27 , wherein the method further comprises administering one or more of an IL-8 antagonist, a MCP-1 antagonist or a sICAM-1 antagonist.

38 . The method of claim 27 , wherein angiogenesis is reduced or attenuated.

39 . The method of claim 27 , wherein said hemichannel blocker is administered by injection.

40 . The method of claim 27 , wherein said hemichannel blocker is administered orally.

41 . The method of claim 27 , wherein the connexin 43 hemichannel blocker is administered PRN (pro re nata) or on a predetermined schedule or both.

42 . The method of claim 27 , wherein the human subject is an adult.

43 . The method of claim 27 , wherein said human subject has a pathological, abnormal, unwanted or undesired amount of cytokine activity.

44 . The method of claim 27 , wherein the amount of connexin 43 hemichannel blocker administered to reduce cytokine levels and/or activities in said human subject is such that the final circulating concentration of said connexin 43 hemichannel blocker in said human subject is from approximately 0.001 to approximately 1000 micromolar.

45 . The method of claim 44 , wherein the final circulating concentration of said connexin 43 hemichannel blocker is from approximately 0.001 up to 200, 300, 400, 500, 600, 700, 800, 900 or 1000 micromolar.

46 . The method of claim 45 , wherein the final circulating concentration of said connexin 43 hemichannel blocker is from approximately 0.001 up to 150 micromolar.

47 . The method of claim 46 , wherein the final circulating concentration of said connexin 43 hemichannel blocker is from approximately 5 to 50 micromolar.

48 . A method for treating a subject having a disease, disorder or condition characterized at least in part by abnormal, elevated, dysregulated, undesired, unwanted or detrimental levels or activities of one or more cytokines selected from the group consisting of IL-6, IL-8, MCP-1, sICAM-1 and vascular endothelial growth factor, comprising administering to said subject an amount of a benzoylamino benzopyran connexin 43 hemichannel blocker according to Formula II effective to reduce the levels and/or activities of said cytokine or cytokines in said subject;

wherein
Q is O or an oxime,
R 2 is H,
A is a direct bond, —C(O)O*-, —C(R 3 )(R 4 )O*-, —C(O O—C(R 3 )(R 4 )O*-, or —C(R 3 )(R 4 )OC(O)O*- wherein the atom marked * is directly connected to R 1 ,
R 3 and R 4 are selected independently from H, fluoro, C 1-4 alkyl, and C 1-4 fluoroalkyl, or R 3 and R 4 together with the atom to which they are attached form a cyclopropyl group,
R 1 is selected from groups [1], [2], [2A], [3], [4], [5] and [6] wherein the atom marked ** is directly connected to A:

wherein R 5 and R 6 are each independently selected from H, C 1-4 alkyl, C 1-4 fluoroalkyl, and benzyl;
R 7 is independently selected from H, C 1-4 alkyl, and C 1-4 fluoroalkyl;
R 8 is selected from:
(i) H, C 1-4 alkyl, or C 1-4 fluoroalkyl,
(ii) the side chain of a natural alpha-amino acid, and
(iii) biotin or chemically linked to biotin;

R 9 is selected from H, —N(R 11 )(R 12 ), —N + (R 11 )(R 12 )(R 13 ) X − , and —N(R 11 )C(O)R 14 ;
wherein R 11 , R 12 , and R 13 are independently selected from H, C 1-4 alkyl, and C 1-4 fluoroalkyl,
R 14 is H, C 1-4 alkyl, or C 1-4 fluoroalkyl,
R 15 is selected from C 1-4 alkyl and C 1-4 fluoroalkyl, and
X − is a pharmaceutically acceptable anion.

49 . A method according to claim 48 , wherein said cytokine is vascular endothelial growth factor.

50 . A method for modulating cytokine activity in a human subject, comprising administering to said human subject an amount of a connexin 43 hemichannel blocker effective to reduce cytokine levels and/or activiti

Assignees

• Auckland Uniservices Ltd
• Ocunexus Therapeutics Inc

Inventors

• Green Colin Richard
• Mugisho Odunayo Omolola Boluwarin
• Duft Bradford James

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K38/10

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61K38/1709 Primary

  from mammals · CPC title